Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camidanlumab tesirine in relapsed/refractory lymphoma
NCT02432235Phase 1Completed
- Sponsor
- ADC Therapeutics
- Start
- Oct 2015
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of camidanlumab tesirine in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (12 arms), sponsored by ADC Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Recommended Dose for Part 2 and 2 more. Started Oct 2015; status: completed.
02
Drugs
camidanlumab tesirine
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02432235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432235.